Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Uproleselan |
| Synonyms | |
| Therapy Description |
Uproleselan (GMI-1271) is a small molecule that binds to E-selectin and prevents E-selectin mediated cell-cell interaction, therefore, modulating inflammation and tumor progression (PMID: 26834953). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Uproleselan | GMI-1271 | Uproleselan (GMI-1271) is a small molecule that binds to E-selectin and prevents E-selectin mediated cell-cell interaction, therefore, modulating inflammation and tumor progression (PMID: 26834953). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02306291 | Phase Ib/II | Cytarabine + Idarubicin Cytarabine + Etoposide + Mitoxantrone Uproleselan | Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML | Completed | USA | IRL | AUS | 0 |